Association Between GalectiN-3 and pOSt-operative atrIal Fibrillation After Coronary Artery bypaSs Graft

N/AActive Not RecruitingNCT06768528

University of Sao Paulo General Hospital90 enrolled

Overview

The goal of this observational study is to test the association between high levels of Galectin-3 and the occurrence of post-operative atrial fibrillation after isolated coronary artery bypass grafting (CABG). The main question\[s\] it aims to answer are: * Is Galectin-3 an accurate biomarker to predict higher risk of developing post-operative atrial fibrillation? * Are high levels of Galectin-3 associated to other post-operative complications and major adverse cardiovascular events? Participants will be enrolled during pre-operative evaluation and a peripheral blood sample collection will be performed in the 24h before CABG. Participants will then be followed for a period of 12 months (daily during hospitalization and 3 appointments after hospital discharge) to determine whether patients with higher levels of Galectin-3 will have worse outcomes.

Prospective, observational, single-center cohort study including patients undergoing coronary artery bypass graft (CABG) surgery. Patients will be enrolled during preoperative evaluation. A peripheral blood sample will be collected within 24 hours before surgery and patients will be followed during hospitalization and for 12 months after discharge.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Post-operative Atrial Fibrillation Cardiovascular Diseases Post-pericardiotomy Syndrome

Interventions

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients undergoing coronary artery bypass graft surgery Exclusion Criteria: * Inability to sign the free and informed consent form * Renal dysfunction with estimated glomerular filtration rate less than 30ml / min / 1.73m² or dialysis therapy * Moderate to severe left ventricular dysfunction (ejection fraction \< 40%) * Patients with previous atrial fibrillation * Pregnancy * Concomitant valve surgery

Outcomes

Primary Outcomes

Galectin-3 and post-operative atrial fibrillation

Evaluate the association of higher levels of Galectin-3 (in ng/mL) and the occurrence of post-operative atrial fibrillation lasting at least 12 hours or requiring cardioversion

Time frame: Up to 7 days after surgery

Secondary Outcomes

Galectin-3 and other post-operative complications

Evaluate the association of higher levels of Galectin-3 (in ng/mL) and the occurrence of post-operative complications, such as infection, acute kidney injury, bleeding, post-pericardiotomy syndrome, reoperation, systemic embolism, type 5 myocardial infarction

Time frame: 6 weeks

Galectin-3 and major adverse cardiovascular events

Evaluate the association of higher levels of Galectin-3 (in ng/mL) and the occurrence major adverse cardiovascular events, such as stroke, acute coronary syndrome, revascularization procedures and cardiovascular death

Time frame: 12 months

Galectin-3 and left atrial remodeling

Evaluate the association of higher levels of Galectin-3 (in ng/mL) and left atrial enlargement (both linear and volumetric echocardiographic measurements) and development of supraventricular arrhythmias in holter monitoring